Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.
Lee J, Jung KH, Park YS, Ahn JB, Shin SJ, Im SA, Oh DY, Shin DB, Kim TW, Lee N, Byun JH, Hong YS, Park JO, Park SH, Lim HY, Kang WK. Lee J, et al. Among authors: ahn jb. Cancer Chemother Pharmacol. 2009 Sep;64(4):657-63. doi: 10.1007/s00280-008-0913-5. Epub 2009 Jan 24. Cancer Chemother Pharmacol. 2009. PMID: 19169686 Clinical Trial.
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
Shin SJ, Ahn JB, Park KS, Lee YJ, Hong YS, Kim TW, Kim HR, Rha SY, Roh JK, Kim DH, Kim C, Chung HC. Shin SJ, et al. Among authors: ahn jb. Invest New Drugs. 2012 Apr;30(2):672-80. doi: 10.1007/s10637-010-9625-x. Epub 2010 Dec 29. Invest New Drugs. 2012. PMID: 21188464 Clinical Trial.
Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01.
Hong YS, Jung KH, Kim HJ, Kim KP, Kim SY, Lee JL, Shim BY, Zang DY, Kim JH, Ahn JB, Park YS, Kim TW. Hong YS, et al. Among authors: ahn jb. Am J Clin Oncol. 2013 Dec;36(6):565-71. doi: 10.1097/COC.0b013e31825d52d5. Am J Clin Oncol. 2013. PMID: 22868243 Clinical Trial.
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Hong YS, Lee SS, Kim KP, Lee JL, Kang YK, Shin SJ, Ahn JB, Jung KH, Im SA, Kim TY, Kim JH, Park YS, Kim TW. Hong YS, et al. Among authors: ahn jb. Am J Clin Oncol. 2014 Feb;37(1):19-23. doi: 10.1097/COC.0b013e31826b9c94. Am J Clin Oncol. 2014. PMID: 23111359 Clinical Trial.
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.
Lee KH, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, Kim SY, Lee KW, Kim JH, Hong YS, Kim TW, Park YS, Kang WK, Shin SJ, Ahn JB, Kang GH, Jeong SY, Park KJ, Park JG, Kim TY. Lee KH, et al. Among authors: ahn jb. Cancer Chemother Pharmacol. 2013 Apr;71(4):843-51. doi: 10.1007/s00280-013-2075-3. Epub 2013 Jan 13. Cancer Chemother Pharmacol. 2013. PMID: 23314736
254 results